Purpose of review Neutrophil extracellular traps (NETs) can be found at the sites of vascular lesions and in the circulation of patients with active small vessel vasculitis. Neutrophils from vasculitis patients release more NETs in vitro, and NETs have properties that can harm the vasculature both directly and indirectly. There are several ways to interfere with NET formation, which open for new therapeutic options. However, there are several types of NETs and different mechanisms of NET formation, and these might have different effects on inflammation. Here we review recent findings regarding the pathogenesis and therapeutic potentials of NETs in vasculitis.
INTRODUCTION
The formation of neutrophil extracellular traps (NETs) was initially described as a mechanism to ensnare and kill invading microorganisms [1] , but in recent years NETs have attracted increased attention in a wide variety of medical conditions such as cancer, thromboembolism, arteriosclerosis, and autoimmune diseases [2] . Kessenbrock et al. [3] suggested a role for NETs in the pathogenesis of vasculitis in 2009, and since then there has been a growing body of literature on the connections between NETs and vasculitis. Here we give an overview of recent advances pertaining to altered NET formation in vasculitis, the relation between NETs and vascular damage, NETs as a source of autoantigens, the utility of biomarkers associated with NETs, and finally some possible therapeutic implications of NET formation in vasculitis. and neutrophil elastase [8] . Neutrophils are not the only cells that can extrude extracellular traps, and eosinophils, basophils, mast cells, and monocytes also have such capacity [9, 10] , and the term ETosis has been coined as a general term for cells releasing extracellular traps. It has been shown that extrusion of NETs is not necessarily associated with cell death, and today many authors distinguish between NETosis involving cell death (suicidal NETosis) and NETosis where the neutrophils remain viable (vital NETosis). NETs released during vital NETosis can consist of nuclear or mitochondrial DNA (mtDNA) and can be released in an NADPH-oxidase and/or reactive oxygen species (ROS)-independent manner [10] [11] [12] [13] .
Primary systemic vasculitis encompasses a wide variety of diseases with idiopathic vascular inflammation as their common defining feature. According to the current nomenclature, they are divided into groups based on the size of the vessels that are predominantly affected in the individual diseases [14] . The small-vessel vasculitides are further grouped according to immunofluorescence findings of biopsies into immune-complex vasculitides and pauci-immune vasculitides. The latter are also referred to as antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) because of their relationship to ANCA, and this group contains the diseases granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly ChurgStrauss syndrome) [14] . More common than primary vasculitis is vasculitis as a complicating feature of other autoimmune diseases, infections, malignancies, or adverse drug reactions [15] .
VASCULITIS IS ASSOCIATED WITH INCREASED FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS
The pathogenesis varies between different forms of vasculitis but at least in small-vessel vasculitis neutrophils have a prominent role. Neutrophils produce ROS and release destructive enzymes, and they attract other players to the scene through the production of cytokines and chemokines. It is often difficult to distinguish the contribution of NETs relative to activation, degranulation, and other forms of neutrophil cell death than NETosis. There are several investigations showing increased NETosis in active vasculitis, and NETs and/or remnants of NETs can be found both in the affected tissues and in the blood circulation of AAV patients [16] . Co-expression of granule proteins (such as MPO and neutrophil elastase) and chromatin (primarily citrullinated histone 3) is often considered as evidence of NETosis. One needs to be aware, however, when screening for NETs that they can also be mitochondrial-derived, and thus would not contain histones.
NETs in AAV were first reported on in kidney biopsies [3] , which was later confirmed by others [17] [18] [19] [20] , and then also in skin specimens [21, 22, 23 && ] and in thrombi [20, 24] of these patients. Neuropathy is another common feature of vasculitis, and NETs were recently shown to be also common in nerve biopsies from AAV patients, but not seen in patients with nonvasculitic demyelinating neuropathy [25 & ]. More NETs were seen in ANCApositive MPA patients compared with ANCA-negative MPA patients and in patients with vasculitis secondary to rheumatoid arthritis [25 & ]. Increased levels of breakdown fragments of NETs (NET remnants) in the circulation have also been reported in vasculitis [3, 26, 27 & ]. In-vitro studies on neutrophils from AAV patients show that they are more prone to undergo spontaneous NETosis [18, 26, 28] and are more responsive to NET-inducing stimuli [29] . Similar findings have been reported in other autoimmune diseases were NETosis is implicated in the pathogenesis [30] [31] [32] ]. This most probably has a bearing on IgA vasculitis, a disease characterized by IgA immune complex deposition and small-vessel leucocytoclastic vasculitis [14] . A recent study on patients with PR3-ANCA-associated vasculitis showed that serum PR3-ANCA IgA levels were more closely related to disease activity than PR3-ANCA IgG levels [44] . 
NEUTROPHIL EXTRACELLULAR TRAPS AND VASCULAR DAMAGE
There are several ways in which NETosis can harm the vasculature, both directly and indirectly. The release of noxious substances such as degrading enzymes can directly induce apoptosis in endothelial cells and degrade the basement membrane [45] , and histones can be toxic to endothelial cells [46] . A recent study showed that endothelial cells can phagocytize NETs, but that excessive amount of NETs promotes vascular leakage by interfering with endothelial cell-cell interactions [47 & ]. The same study also showed that NETs can induce endothelial to mesenchymal transformation (EndMT) and that such cells are increased in the glomeruli, both in MLR/lpr mice (a mouse model of SLE) as well as in patients with lupus nephritis [47 & ]. EndMT is important during vascular repair but it is also connected to several disease conditions as it contributes to tissue fibrosis [48] , which is a common feature in vasculitis. Indirectly, NETs promote vascular damage by activating the alternative complement pathway [49] .
Renal injury is common in small vessel vasculitis, including both glomerulonephritis with crescent formation and tubulointerstitial nephritis. 
NEUTROPHIL EXTRACELLULAR TRAPS CAN BE PROTECTIVE
A recent study showed that saliva can induce NETs, and that this capacity is diminished in Bechet's disease, a form of primary vasculitis characterized by mouth and genital ulcers [8] . The authors argued that the absence of NETs leads to diminished protection against bacteria on the mucus membranes and that this promotes ulcer formation. Other examples, in which reduced NETosis leads to more severe disease are mouse models of SLE [54 && ] and gout [55] . These studies suggest that NETs can act as platforms to degrade proinflammatory mediators that would otherwise drive inflammation. Additionally, NETs can impair GM-CSF/IL-4-induced dendritic cell differentiation from monocytes in vitro, and can instead promote an alternatively activated macrophage phenotype [56 & ]. This subgroup of macrophages is important for the resolution of inflammation, which is crucial for preventing chronic inflammation.
ANTIGEN EXPOSURE IN NEUTROPHIL EXTRACELLULAR TRAPS PROMOTES THE PRODUCTION OF AUTOANTIBODIES
NETs contain an array of molecular motifs that serve as targets for autoantibodies in autoimmune diseases, including double-stranded DNA in SLE [32] , citrullinated peptides in rheumatoid arthritis [31] , and MPO and PR3 in AAV [3] . NETs can also contain alarmins, such as LL39 and HMGB1 [57, 58] , which provide danger signals, and thus reduce immunological tolerance. The strongest evidence that NETs actually serve as a source of autoantigens driving autoantibody production in vasculitis comes from studies on drug-induced vasculitis. MPO-ANCA positivity is relatively common in patients treated with the antithyroid drug propylthiouracil (PTU), and some of these patients develop a vasculitis-like syndrome [59] . Phorbol 12-myrsetate 13-acetate (PMA) in combination with the antithyroid drug PTU induces NETs that resist DNase I degradation, and such NETs cause the production of ANCAs and AAV-like disease in rats [60] . Using a similar approach as above but in a mouse model, PMA and PTU again resulted in the production of MPO-ANCA, but did not induce disease [ 
NEUTROPHIL EXTRACELLULAR TRAPS AS A BIOMARKER
Monitoring of disease activity is an unmet need in vasculitis, and better monitoring will enable more efficient use of the drugs available today and will reduce the side effects of maintenance therapy. As reviewed elsewhere [16] , several studies in recent years have reported on increased levels of NETs and NET-associated proteins in the circulation of AAV patients that often correlate with disease activity. However, there is no assay available today that has proven to be clinically useful. Measurements of NETs suffer from a lack of standardisation, as well as from problems with sensitivity and specificity. As a result of this, there are currently no general values for these parameters regarding the presence of NETs in various diseases. The fact that ANCAs of different affinities appear to vary in their NET-inducing capacity encourages further studies with this approach to evaluate its usefulness to monitor disease activity [34] . The capacity for serum to degrade NETs is another tempting approach, and this capacity is reduced in serum from AAV patients [34] . DNase I activity did not vary with disease activity in that study, but NET degradation per se with serum from patients with various disease activities was not evaluated. Regardless of the methodological approach, further evaluation of NETs as a biomarker to monitor disease activity in AAV (alone or in combination with other parameters) requires carefully undertaken longitudinal studies.
IMPLICATIONS FOR TREATMENT
As summarized in Table 2 , several approaches have been used in recent studies to block the effect of NETs on vascular damage in different in vivo experimental models. Antihistone treatment through antihistone antibodies, heparin, or activated protein C all proved to be efficient in treating anti-GBM-induced vasculitis [46] . This was also the case for the PAD inhibitor Cl-amidine [46] , which inhibits the citrullination of histones that is an important step during suicidal NETosis. Inhibiting PAD signalling was also shown to be efficient in a mouse model There is a plethora of other molecules that are being tested for their ability to block NETosis, and these are primarily being evaluated in vitro. A recent example is the blockade of neutrophil elastase, which has been shown to inhibit NET-induced disruption of endothelial cell-cell integrity and EndMT [48] . Although inhibition of NADPH oxidase is effective in inhibiting suicidal NETosis in vitro, Table 2 . Therapeutic approaches that inhibit or reduce the effect of neutrophil extracellular traps on vascular damage AAV, antineutrophil cytoplasmic autoantibody-associated vasculitis; AKI, acute kidney injury; AT-MSC, adipocyte tissue-derived mesenchymal stem cell; BSA, bovine serum albumin; GBM, glomerular basement membrane; mtROS, mitochondrial reactive oxygen species; PAD, peptidyl arginine deiminase; SLE, systemic lupus erythematosus; SOD3, superoxide dismutase 3.
recent studies on experimental mouse models of SLE [54 && ] and gout [55] , both of which lack NADPH oxidase, show more severe diseases. In line with these studies, patients with chronic granulomatos disease, with defective NADPH oxidase, have a greater incidence of autoimmune diseases [63] . Low-density granulocytes (LDGs) are the neutrophil subpopulation that release the most NETs both in AAV [28] and SLE [32] ]. Thus, targeting these NETs might also be an interesting approach in AAV. Regarding PAD4, which was shown to be a good target in various mouse models to limit NETmediated inflammation, it was shown in the same study as for NADPH oxidase that PAD4 À/À mice developed worse disease than control mice [54 && ]. It appears that a certain amount of ROS signalling and NETosis is important to limit inflammation, whereas excessive NETs can instead cause disease.
A recent example of compounds tested in vitro relevant to this aspect is the tetrahydroisoquinolines that can inhibit NETosis without interfering with ROS production [64 & ]. These were shown to inhibit both spontaneous and PMA-induced NETosis in neutrophils from SLE patients.
DNase I, which efficiently degrades DNA and thus degrades NETs, is already being used clinically and has proven to be well tolerated. However, a phase 1 clinical study of DNase I in SLE patients did not show any effect on double-stranded DNA autoantibody production, inflammatory markers, or disease severity [65] . When applied in a mouse model of anti-GBM-induced glomerulonephritis, DNase I rescued mice from haematuria, but not proteinuria [50 & ]. It appears that components of NETs such as histones and neutrophil elastase can still harm the vasculature after DNase I treatment [66] . It is worth noting that the complement fragment C5a can also induce NETosis [11] , and a recent randomized controlled trial in AAV patients showed that the C5a receptor inhibitor avacopan had positive effects on disease activity [67] .
CONCLUSION
Several studies have taken different approaches in studying the role of NETs in vasculitis, including in vitro functional studies, drug-induced autoimmunity, and animal models, and these have proposed NETs to constitute a source of autoantibodies and to promote vascular damage. These events can be avoided or reversed by inhibiting NETosis, blocking the proteins that are present in NETs, or by clearing NETs that have already formed. It would, however, be valuable for our understanding of NETs in vasculitis to learn more about why some animal models of autoimmune disease with impaired NETosis show aggravation of disease. This study presents a novel sensitive approach to quantify NETs. This is a good approach because no NETs are being washed away before quantification.
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